ijms-logo

Journal Browser

Journal Browser

Genetic and Genomic Diagnostics for Rare Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 559

Special Issue Editor


E-Mail Website
Guest Editor
Department of Health Sciences, Magna Graecia University, 88100 Catanzaro, Italy
Interests: genetics; X-linked disease; kidney disease; rare diseases

Special Issue Information

Dear Colleagues,

Genomic technologies such as targeted, exome and short-read genome sequencing have revolutionized the care of patients with rare genetic diseases. However, more than half of patients remain undiagnosed. Rare diseases are heterogeneous, life-threatening or severely debilitating conditions that affect < 1 in 2000 individuals. Emerging research-based approaches such as long-read genome sequencing and optical genome mapping promise to improve the identification of disease-causing genetic variants. In addition, new omics technologies that measure the transcriptome, epigenome, proteome or metabolome are showing great potential for variant interpretation. With the rapid expansion of genetic testing options, the clinical community needs to be aware of their individual strengths and limitations, as well as remaining challenges, in order to select the appropriate diagnostic test, correctly interpret results, and drive innovation to fill research gaps. 

This Special Issue aims to understand whether these multi-omics approaches are actually being integrated into clinical research and how these technologies are improving the interpretive power of genetic and genomic diagnostics for rare diseases.

Dr. Antonella La Russa
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genome sequencing
  • molecular diagnosis
  • rare diseases
  • multi-omics
  • next-generation sequencing
  • long-read RNA-Seq

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 1313 KiB  
Case Report
Potential Pathogenetic Role of the D313Y Mutation in the GLA Gene in Anderson Fabry Disease: Two Case Reports
by Antonella La Russa, Antonio Siniscalchi, Ardito Bonaventura, Domenico Di Noia, Teresa Valsania, Giovanni Stallone, Luciano Tartaglia, Concetta Chiapparino, Giovanni Di Rienzo, Giuseppe Coppolino, Davide Bolignano, Teresa Faga, Ashour Michael, Alberto Montesanto, Raffaele Serra and Michele Andreucci
Int. J. Mol. Sci. 2025, 26(9), 4400; https://doi.org/10.3390/ijms26094400 - 6 May 2025
Viewed by 396
Abstract
Anderson Fabry disease (AFD) is an X-linked hereditary lysosomal abnormality that causes the accumulation of glycosphingolipids in body fluids and tissues, leading to progressive organ damage and a shortened life span. More than 1000 mutations in the GLA gene have been identified, promoting [...] Read more.
Anderson Fabry disease (AFD) is an X-linked hereditary lysosomal abnormality that causes the accumulation of glycosphingolipids in body fluids and tissues, leading to progressive organ damage and a shortened life span. More than 1000 mutations in the GLA gene have been identified, promoting many different clinical pictures. For this reason, diagnosing AFD can be difficult, especially because of the great diversity of atypical clinical presentations that can simulate the disease. Some of these variants of the GLA gene have been described as non-pathogenic. For example, the D313Y variant is one of the most controversial, even if there are several case reports of D313Y patients presenting with signs and symptoms consistent with AFD without any other etiological explanation. This work aimed to clarify whether the presence of the D313Y variant affects α-Gal A activity and causes AFD symptoms and organ involvement in two patients from different families. The presence of the D313Y variant resulted in clinical manifestations of AFD in both patients and a decrease in alpha-galactosidase activity in the male patient. Two patients (one female and one male) from two unrelated families were examined. Sequencing of all seven GLA exons and the adjacent 5′ and 3′ exon–intron boundaries identified the D313Y variant in exon 6, as well as the genetic variation g.1170C>T in the flanking 5′ UTR in patient 1 only. Our results suggest that the D313Y variant is causative for the disease and that the clinical phenotype can be enhanced by the presence of other variants modulating protein expression. Full article
(This article belongs to the Special Issue Genetic and Genomic Diagnostics for Rare Diseases)
Show Figures

Figure 1

Back to TopTop